David Bonita - Tricida Chairman of the Board

TCDA -- USA Stock  

USD 41.40  0.57  1.40%

  Chairman
Dr. David P. Bonita, M.D., serves as Independent Director of the Company. Dr. Bonita has served as a member of our board of directors since January 2014. Since June 2013, Dr. Bonita has held the position of Private Equity Partner at OrbiMed Advisors LLC, an affiliate of one of our principal stockholders. From June 2004 to June 2013, Dr. Bonita held other positions at OrbiMed. Dr. Bonita has served on the boards of directors of Clementia Pharmaceuticals Inc. and SiBone, Inc. since April 2013 and April 2014, respectively. Dr. Bonita also previously served on the boards of directors of Ambit Biosciences Corporationrationration, Loxo Oncology, Inc. and ViewRay Inc. Dr. Bonita currently serves on the boards of directors of the following private companies Acutus Medical Inc., Imara Inc., Kyn Therapeutics Inc., Prelude Therapeutics Inc. and Sublimity Therapeutics, Inc. and has previously served on the board of directors of CardiAQ Valve Technologies, Cryterion Medical Inc., Enobia Pharma Inc. and Keystone Heart Ltd
Age: 42  Chairman Since 2014  MBA    
415-429-7800  http://www.tricida.com
Bonita has also worked as a corporate finance analyst in the healthcare investment banking groups of Morgan Stanley and UBS. He has published scientific articles in peerreviewed journals based on signal transduction research performed at Harvard Medical School. He received his A.B. in Biological Sciences from Harvard University and his joint M.D./M.B.A. from Columbia University.

David Bonita Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (29.02) % which means that it has lost $29.02 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (55.2) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 47.99 M in liabilities with Debt to Equity (D/E) ratio of 15.4 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Tricida has Current Ratio of 15.17 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

CHAIRMAN Since

Eric SchmidtAlphabet
2018
Yun MaAlibaba Group Holding Limited
2013
Jeffrey BezosAmazon Com
2000
Peter ScherJP Morgan Chase Co
2017
John ThompsonMicrosoft Corporation
2014
Joseph TsaiAlibaba Group Holding Limited
2013
Vasant PrabhuVisa
2019
Mark ZuckerbergFacebook
2012
Valentino SyVisa
2005
Alfred KellyVisa
2019
Arthur LevinsonApple
2011
Art LevinsonApple
2011
Robert MatschullatVisa
2019
Ellen RicheyVisa
2014
James DimonJP Morgan Chase Co
2018

Entity Summary

Tricida, Inc., a pharmaceutical company, focuses on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease . Tricida, Inc. was founded in 2013 and is headquartered in South San Francisco, California. Tricida is traded on BATS Exchange in USA.Tricida (TCDA) is traded on BATS Exchange in USA and employs 104 people.

Tricida Leadership Team

Jerry Buysse, Senior Vice President Chief Scientific Officer
Wilhelm Stahl, Senior Vice President CTO
Robert Alpern, Independent Director
Edward Hejlek, Senior Vice President General Counsel
Geoffrey Parker, CFO, Senior Vice President
David Hirsch, Independent Director
Claire Lockey, Senior Vice President and Chief Development Officer
David Bonita, Chairman of the Board
Sandra Coufal, Independent Director
Gerrit Klaerner, President CEO, Member of the Board of Directors
Jeroen Beek, Chief Commercial Officer and Senior Vice President
Kathryn Falberg, Independent Director
Klaus Veitinger, Independent Chairman of the Board
Dawn Parsell, Senior Vice President - Clinical Development
Susannah Cantrell, Senior Vice President Chief Commercial Officer

Stock Performance Indicators

Current Sentiment - TCDA

Tricida Investor Sentiment

Macroaxis portfolio users are evenly split in their outlook on investing in Tricida. What is your outlook on investing in Tricida? Are you bullish or bearish?
Bullish
Bearish
50% Bullish
50% Bearish
Skip

Currently Active Assets on Macroaxis

CAE   
Purchased few shares of
a day ago
Traded for 26.59
UNP   
Purchased few shares of
a day ago
Traded for 175.48
FEYE   
Purchased few shares of
a day ago
Traded for 17.11
PM   
Purchased few shares of
a day ago
Traded for 83.77
PSTG   
Purchased few shares of
a day ago
Traded for 20.19
Also please take a look at World Market Map. Please also try Chance of Distress module to get analysis of equity chance of financial distress in the next 2 years.
Search macroaxis.com